Top

Published in:

Open Access 01-11-2020 | Original Article

Differences in the sensitivity of classically and alternatively activated macrophages to TAK1 inhibitor-induced necroptosis

Authors: Zsófia Varga, Tamás Molnár, Anett Mázló, Ramóna Kovács, Viktória Jenei, Krisztina Kerekes, Attila Bácsi, Gábor Koncz

Published in: Cancer Immunology, Immunotherapy | Issue 11/2020

Abstract

Controlling the balance of pro-inflammatory M1 versus anti-inflammatory M2 macrophages may have paramount therapeutic benefit in cardiovascular diseases, infections, cancer and chronic inflammation. The targeted depletion of different macrophage populations provides a therapeutic option to regulate macrophage-mediated functions. Macrophages are highly sensitive to necroptosis, a newly described regulated cell death mediated by receptor-interacting serine/threonine-protein kinase 1 (RIPK1), RIPK3 and mixed lineage kinase domain like pseudokinase. Antagonists of inhibitors of apoptosis proteins (SMAC mimetics) block RIPK1 ubiquitination, while TGF-activated kinase 1 (TAK1) inhibitors prevent the phosphorylation of RIPK1, resulting in increased necroptosis. We compared the sensitivity of monocyte-derived human M1 and M2 cells to various apoptotic and necroptotic signals. The two cell types were equally sensitive to all investigated stimuli, but TAK1 inhibitor induced more intense necroptosis in M2 cells. Consequently, the treatment of co-cultured M1 and M2 cells with TAK1 inhibitor shifted the balance of the two populations toward M1 dominance. Blockage of either Aurora Kinase A or glycogen synthase kinase 3β, two newly described necroptosis inhibitors, increased the sensitivity of M1 cells to TAK1-inhibitor-induced cell death. Finally, we demonstrated that in vitro differentiated tumor-associated macrophages (TAM-like cells) were as highly sensitive to TAK1 inhibitor-induced necroptosis as M2 cells. Our results indicate that at least two different necroptotic pathways operate in macrophages and the targeted elimination of different macrophage populations by TAK1 inhibitor or SMAC mimetic may provide a therapeutic option to regulate the balance of inflammatory/anti-inflammatory macrophage functions.

Available only for authorised users

Mills CD (2015) Anatomy of a discovery: m1 and m2 macrophages. Front Immunol 6:212. https://doi.org/10.3389/fimmu.2015.00212CrossRefPubMedPubMedCentral

Zotes TM, Arias CF, Fuster JJ, Spada R, Perez-Yague S, Hirsch E, Wymann M, Carrera AC, Andres V, Barber DF (2013) PI3K p110gamma deletion attenuates murine atherosclerosis by reducing macrophage proliferation but not polarization or apoptosis in lesions. PLoS ONE 8(8):e72674. https://doi.org/10.1371/journal.pone.0072674CrossRefPubMedPubMedCentral

Liu W, Zhang X, Zhao M, Zhang X, Chi J, Liu Y, Lin F, Fu Y, Ma D, Yin X (2015) Activation in M1 but not M2 macrophages contributes to cardiac remodeling after myocardial infarction in rats: a critical role of the calcium sensing receptor/NRLP3 inflammasome. Cell Physiol Biochem 35(6):2483–2500. https://doi.org/10.1159/000374048CrossRefPubMed

Yu T, Zhao L, Huang X, Ma C, Wang Y, Zhang J, Xuan D (2016) Enhanced activity of the macrophage M1/M2 phenotypes and phenotypic switch to M1 in periodontal infection. J Periodontol 87(9):1092–1102. https://doi.org/10.1902/jop.2016.160081CrossRefPubMed

Quatromoni JG, Eruslanov E (2012) Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res 4(4):376–389PubMedPubMedCentral

DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 19(6):369–382. https://doi.org/10.1038/s41577-019-0127-6CrossRefPubMedPubMedCentral

Eapen MS, Hansbro PM, McAlinden K, Kim RY, Ward C, Hackett TL, Walters EH, Sohal SS (2017) Abnormal M1/M2 macrophage phenotype profiles in the small airway wall and lumen in smokers and chronic obstructive pulmonary disease (COPD). Sci Rep 7(1):13392. https://doi.org/10.1038/s41598-017-13888-xCrossRefPubMedPubMedCentral

Verdeguer F, Aouadi M (2017) Macrophage heterogeneity and energy metabolism. Exp Cell Res 360(1):35–40. https://doi.org/10.1016/j.yexcr.2017.03.043CrossRefPubMed

Tardito S, Martinelli G, Soldano S, Paolino S, Pacini G, Patane M, Alessandri E, Smith V, Cutolo M (2019) Macrophage M1/M2 polarization and rheumatoid arthritis: a systematic review. Autoimmun Rev 18(11):102397. https://doi.org/10.1016/j.autrev.2019.102397CrossRefPubMed

10.

Quaranta V, Schmid MC (2019) Macrophage-mediated subversion of anti-tumour immunity. Cells 8(7):747. https://doi.org/10.3390/cells8070747CrossRefPubMedCentral

11.

Parihar A, Eubank TD, Doseff AI (2010) Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death. J Innate Immun 2(3):204–215. https://doi.org/10.1159/000296507CrossRefPubMedPubMedCentral

12.

Schilling R, Geserick P, Leverkus M (2014) Characterization of the ripoptosome and its components: implications for anti-inflammatory and cancer therapy. Methods Enzymol 545:83–102. https://doi.org/10.1016/B978-0-12-801430-1.00004-4CrossRefPubMed

13.

Griewahn L, Koser A, Maurer U (2019) keeping cell death in check: ubiquitylation-dependent control of TNFR1 and TLR signaling. Front Cell Dev Biol 7:117. https://doi.org/10.3389/fcell.2019.00117CrossRefPubMedPubMedCentral

14.

Sanjo H, Nakayama J, Yoshizawa T, Fehling HJ, Akira S, Taki S (2019) Cutting edge: TAK1 safeguards macrophages against proinflammatory cell death. J Immunol 203(4):783–788. https://doi.org/10.4049/jimmunol.1900202CrossRefPubMed

15.

Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J (2000) Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 1(6):489–495. https://doi.org/10.1038/82732CrossRefPubMed

16.

He S, Wang L, Miao L, Wang T, Du F, Zhao L, Wang X (2009) Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137(6):1100–1111CrossRefPubMed

17.

Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, Liu Z-G (2012) Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci USA 109(14):5322–5327. https://doi.org/10.1073/pnas.1200012109CrossRefPubMedPubMedCentral

18.

Molnar T, Mazlo A, Tslaf V, Szollosi AG, Emri G, Koncz G (2019) Current translational potential and underlying molecular mechanisms of necroptosis. Cell Death Dis 10(11):860. https://doi.org/10.1038/s41419-019-2094-zCrossRefPubMedPubMedCentral

19.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D’Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, Garcia-Saez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jaattela M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, Lopez-Otin C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Munoz-Pinedo C, Nagata S, Nunez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25(3):486–541. https://doi.org/10.1038/s41418-017-0012-4CrossRefPubMedPubMedCentral

20.

Lin Y, Devin A, Rodriguez Y, Liu ZG (1999) Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev 13(19):2514–2526CrossRefPubMedPubMedCentral

21.

Vanden Berghe T, Kaiser WJ, Bertrand MJ, Vandenabeele P (2015) Molecular crosstalk between apoptosis, necroptosis, and survival signaling. Mol Cell Oncol 2(4):e975093. https://doi.org/10.4161/23723556.2014.975093CrossRefPubMedPubMedCentral

22.

O’Donnell MA, Perez-Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R, Green DR, Ting AT (2011) Caspase 8 inhibits programmed necrosis by processing CYLD. Nat Cell Biol 13(12):1437–1442CrossRefPubMedPubMedCentral

23.

Park SM, Yoon JB, Lee TH (2004) Receptor interacting protein is ubiquitinated by cellular inhibitor of apoptosis proteins (c-IAP1 and c-IAP2) in vitro. FEBS Lett 566(1–3):151–156. https://doi.org/10.1016/j.febslet.2004.04.021CrossRefPubMed

24.

Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281(5383):1680–1683CrossRefPubMed

25.

Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J (2001) NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 21(16):5299–5305. https://doi.org/10.1128/MCB.21.16.5299-5305.2001CrossRefPubMedPubMedCentral

26.

Guo X, Yin H, Chen Y, Li L, Li J, Liu Q (2016) TAK1 regulates caspase 8 activation and necroptotic signaling via multiple cell death checkpoints. Cell Death Dis 7(9):e2381. https://doi.org/10.1038/cddis.2016.294CrossRefPubMedPubMedCentral

27.

Dondelinger Y, Jouan-Lanhouet S, Divert T, Theatre E, Bertin J, Gough PJ, Giansanti P, Heck AJ, Dejardin E, Vandenabeele P, Bertrand MJ (2015) NF-kappaB-independent role of IKKalpha/IKKbeta in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death during TNF signaling. Mol Cell 60(1):63–76. https://doi.org/10.1016/j.molcel.2015.07.032CrossRefPubMed

28.

Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E, Feltham R, Vince J, Warnken U, Wenger T, Koschny R, Komander D, Silke J, Walczak H (2009) Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 36(5):831–844. https://doi.org/10.1016/j.molcel.2009.10.013CrossRefPubMed

29.

Jaco I, Annibaldi A, Lalaoui N, Wilson R, Tenev T, Laurien L, Kim C, Jamal K, Wicky John S, Liccardi G, Chau D, Murphy JM, Brumatti G, Feltham R, Pasparakis M, Silke J, Meier P (2017) MK2 Phosphorylates RIPK1 to prevent TNF-induced cell death. Mol Cell 66(5):698–710 e695. https://doi.org/10.1016/j.molcel.2017.05.003CrossRef

30.

Xie Y, Zhu S, Zhong M, Yang M, Sun X, Liu J, Kroemer G, Lotze M, Zeh HJ 3rd, Kang R, Tang D (2017) Inhibition of aurora Kinase A induces necroptosis in pancreatic carcinoma. Gastroenterology 153(5):1429–1443 e1425. https://doi.org/10.1053/j.gastro.2017.07.036CrossRef

31.

Siegmund D, Kums J, Ehrenschwender M, Wajant H (2016) Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis. Cell Death Dis 7(9):e2375. https://doi.org/10.1038/cddis.2016.285CrossRefPubMedPubMedCentral

32.

Mia S, Warnecke A, Zhang XM, Malmstrom V, Harris RA (2014) An optimized protocol for human M2 macrophages using M-CSF and IL-4/IL-10/TGF-beta yields a dominant immunosuppressive phenotype. Scand J Immunol 79(5):305–314. https://doi.org/10.1111/sji.12162CrossRefPubMedPubMedCentral

33.

Raggi F, Pelassa S, Pierobon D, Penco F, Gattorno M, Novelli F, Eva A, Varesio L, Giovarelli M, Bosco MC (2017) Regulation of human macrophage M1–M2 polarization balance by hypoxia and the triggering receptor expressed on myeloid cells-1. Front Immunol 8:1097. https://doi.org/10.3389/fimmu.2017.01097CrossRefPubMedPubMedCentral

34.

Benner B, Scarberry L, Suarez-Kelly LP, Duggan MC, Campbell AR, Smith E, Lapurga G, Jiang K, Butchar JP, Tridandapani S, Howard JH, Baiocchi RA, Mace TA, Carson WE 3rd (2019) Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro. J Immunother Cancer 7(1):140. https://doi.org/10.1186/s40425-019-0622-0CrossRefPubMedPubMedCentral

35.

Lin Y, Xu J, Lan H (2019) Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol 12(1):76. https://doi.org/10.1186/s13045-019-0760-3CrossRefPubMedPubMedCentral

36.

Sawa-Wejksza K, Kandefer-Szerszen M (2018) Tumor-associated macrophages as target for antitumor therapy. Arch Immunol Ther Exp (Warsz) 66(2):97–111. https://doi.org/10.1007/s00005-017-0480-8CrossRef

37.

Elliott LA, Doherty GA, Sheahan K, Ryan EJ (2017) Human tumor-infiltrating myeloid cells: phenotypic and functional diversity. Front Immunol 8:86. https://doi.org/10.3389/fimmu.2017.00086CrossRefPubMedPubMedCentral

38.

Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545(7655):495–499. https://doi.org/10.1038/nature22396CrossRefPubMedPubMedCentral

39.

Nally FK, De Santi C, McCoy CE (2019) Nanomodulation of macrophages in multiple sclerosis. Cells 8(6):543. https://doi.org/10.3390/cells8060543CrossRefPubMedCentral

40.

Lagana AS, Salmeri FM, Ban Frangez H, Ghezzi F, Vrtacnik-Bokal E, Granese R (2019) Evaluation of M1 and M2 macrophages in ovarian endometriomas from women affected by endometriosis at different stages of the disease. Gynecol Endocrinol. https://doi.org/10.1080/09513590.2019.1683821CrossRefPubMed

41.

Fulda S (2017) Smac mimetics to therapeutically target IAP proteins in cancer. Int Rev Cell Mol Biol 330:157–169. https://doi.org/10.1016/bs.ircmb.2016.09.004CrossRefPubMed

42.

Sakurai H (2012) Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci 33(10):522–530. https://doi.org/10.1016/j.tips.2012.06.007CrossRefPubMed

43.

Park J, Kim HD, Lee SH, Kwak CH, Chang YC, Lee YC, Chung TW, Magae J, Kim CH (2019) Ascochlorin induces caspase-independent necroptosis in LPS-stimulated RAW 264.7 macrophages. J Ethnopharmacol 239:111898. https://doi.org/10.1016/j.jep.2019.111898CrossRefPubMed

44.

Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J (2017) Aurora kinases: novel therapy targets in cancers. Oncotarget 8(14):23937–23954. https://doi.org/10.18632/oncotarget.14893CrossRefPubMedPubMedCentral

45.

Amin P, Florez M, Najafov A, Pan H, Geng J, Ofengeim D, Dziedzic SA, Wang H, Barrett VJ, Ito Y, LaVoie MJ, Yuan J (2018) Regulation of a distinct activated RIPK1 intermediate bridging complex I and complex II in TNFalpha-mediated apoptosis. Proc Natl Acad Sci U S A 115(26):E5944–E5953. https://doi.org/10.1073/pnas.1806973115CrossRefPubMedPubMedCentral

Title: Differences in the sensitivity of classically and alternatively activated macrophages to TAK1 inhibitor-induced necroptosis
Authors: Zsófia Varga
Tamás Molnár
Anett Mázló
Ramóna Kovács
Viktória Jenei
Krisztina Kerekes
Attila Bácsi
Gábor Koncz
Publication date: 01-11-2020
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 11/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02623-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2020

Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer

In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer

Expression profiles and function of IL6 in polymorphonuclear myeloid-derived suppressor cells

Immune resilience in response to cancer therapy

CD200 is overexpressed in neuroblastoma and regulates tumor immune microenvironment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer